Abstract 401P
Background
Academic field in oncology is male dominated in India as it is in the rest of the world. There is a dearth of female oncologists in managerial or leadership posts in oncology. Female oncologists face unique challenges in this field. Female authorship as first or corresponding author is a surrogate marker for the representation of females in the academic world. This study was undertaken to determine the extent of female participation/leadership in oncology in India.
Methods
An online survey was conducted across the women in the field of oncology in India. Also, the issues of Indian Journal of Cancer and Indian Journal of Medical and Paediatric Oncology from January 2017 to December 2018 were examined. The articles with female first or corresponding authors were enumerated.
Results
Of the 153 participants in the survey, 56% were above 40 years of age. 53% of them were clinical oncologists. 65% of the females worked in male majority teams and 67% admitted to working with male managers. Only 31% of the respondents covered a leadership role within their jobs. Family commitments, perception of males as the natural leaders and maintaining a work family balance were quoted to be the most frequent obstacles to career progression. A total of 558 journal publications were inspected. Of these, 145 articles (26%) had a female first author or a corresponding author, of which 94 (64.9%) were original articles. Each issue had a median of 30 publications, of which median of 8 publications (range 3-15) were authored by females. Of the 360 original articles perused, only 94 (26.1%) had female authorship.
Conclusions
This study was undertaken to analyse the participation of females in oncology and allied sciences in India. Only 1/3 of the females were in a leadership position of the 153 survey participants. Majority of the females work in male-dominated work environments and tackle multitude of impediments in advancement in their profession. Objectively, only 26% of the publications in two of the leading oncology journals of India were authored by females. Female first/corresponding authors were found only in 26% of the original articles. More efforts are to be taken for women empowerment and increase the representation of females in this field. More flexible work/training schedules are required for their upliftment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract